XML 84 R28.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenue (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2020
Revenue From Contract With Customer [Abstract] |
Composition of Total Revenue by Product and by U.S versus Rest of World | The following table presents detail regarding the composition of our total revenue by product and by U.S versus rest of world, “RoW”:
|  | Three months ended March 31, |
|  | 2020 |  |  | 2019 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 81.3 |  |  | $ | 3.9 |  |  | $ | 85.2 |  |  | $ | 114.3 |  |  | $ | 3.3 |  |  | $ | 117.6 |
GeneSight |  |  | 20.4 |  |  |  | — |  |  |  | 20.4 |  |  |  | 29.6 |  |  |  | — |  |  |  | 29.6 |
Prenatal |  |  | 20.2 |  |  |  | 0.1 |  |  |  | 20.3 |  |  |  | 30.6 |  |  |  | — |  |  |  | 30.6 |
Vectra |  |  | 10.5 |  |  |  | — |  |  |  | 10.5 |  |  |  | 11.3 |  |  |  | — |  |  |  | 11.3 |
Prolaris |  |  | 6.8 |  |  |  | — |  |  |  | 6.8 |  |  |  | 6.9 |  |  |  | — |  |  |  | 6.9 |
EndoPredict |  |  | 0.6 |  |  |  | 2.9 |  |  |  | 3.5 |  |  |  | 0.5 |  |  |  | 2.3 |  |  |  | 2.8 |
Other |  |  | 3.6 |  |  |  | 0.2 |  |  |  | 3.8 |  |  |  | 1.5 |  |  |  | 0.2 |  |  |  | 1.7 |
Total molecular diagnostic revenue |  |  | 143.4 |  |  |  | 7.1 |  |  |  | 150.5 |  |  |  | 194.7 |  |  |  | 5.8 |  |  |  | 200.5 |
Pharmaceutical and clinical service revenue |  |  | 9.6 |  |  |  | 3.9 |  |  |  | 13.5 |  |  |  | 9.7 |  |  |  | 6.4 |  |  |  | 16.1 |
Total revenue |  | $ | 153.0 |  |  | $ | 11.0 |  |  | $ | 164.0 |  |  | $ | 204.4 |  |  | $ | 12.2 |  |  | $ | 216.6 |
|  | Nine months ended March 31, |
|  | 2020 |  |  | 2019 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 295.0 |  |  | $ | 12.6 |  |  | $ | 307.6 |  |  | $ | 351.4 |  |  | $ | 9.3 |  |  | $ | 360.7 |
GeneSight |  |  | 65.6 |  |  |  | — |  |  |  | 65.6 |  |  |  | 82.8 |  |  |  | — |  |  |  | 82.8 |
Prenatal |  |  | 59.9 |  |  |  | 0.2 |  |  |  | 60.1 |  |  |  | 80.0 |  |  |  | — |  |  |  | 80.0 |
Vectra |  |  | 31.8 |  |  |  | — |  |  |  | 31.8 |  |  |  | 36.1 |  |  |  | — |  |  |  | 36.1 |
Prolaris |  |  | 20.0 |  |  |  | 0.1 |  |  |  | 20.1 |  |  |  | 19.1 |  |  |  | 0.1 |  |  |  | 19.2 |
EndoPredict |  |  | 1.5 |  |  |  | 6.8 |  |  |  | 8.3 |  |  |  | 1.2 |  |  |  | 6.2 |  |  |  | 7.4 |
Other |  |  | 9.9 |  |  |  | 0.2 |  |  |  | 10.1 |  |  |  | 5.8 |  |  |  | 0.5 |  |  |  | 6.3 |
Total molecular diagnostic revenue |  |  | 483.7 |  |  |  | 19.9 |  |  |  | 503.6 |  |  |  | 576.4 |  |  |  | 16.1 |  |  |  | 592.5 |
Pharmaceutical and clinical service revenue |  |  | 26.3 |  |  |  | 15.5 |  |  |  | 41.8 |  |  |  | 25.5 |  |  |  | 17.7 |  |  |  | 43.2 |
Total revenue |  | $ | 510.0 |  |  | $ | 35.4 |  |  | $ | 545.4 |  |  | $ | 601.9 |  |  | $ | 33.8 |  |  | $ | 635.7 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
|  | Nine months ended |
|  | March 31, |
|  | 2020 |  |  | 2019 |
Deferred revenue - beginning balance |  | $ | 2.2 |  |  | $ | 2.6 |
Revenue recognized |  |  | (2.4 | ) |  |  | (5.9 | )
Prepayments |  |  | 4.0 |  |  |  | 5.6 |
Deferred revenue - Ending Balance |  | $ | 3.8 |  |  | $ | 2.3 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration